Cargando…

Correction: Continuing a cancer treatment despite tumor growth may be valuable: Sunitinib in renal cell carcinoma as example

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117539/ http://dx.doi.org/10.1371/journal.pone.0105179

Ejemplares similares

Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example
por: Burotto, Mauricio, et al.
Publicado: (2014)

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2018)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Correction to: PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
por: Feng, Chenchen, et al.
Publicado: (2021)

Correction: ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma
por: Zhu, Liangsong, et al.
Publicado: (2021)

Correction: Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma
por: Ruan, Hailong, et al.
Publicado: (2022)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
por: Blagoev, Krastan B., et al.
Publicado: (2013)

Correction: Antibiotic Innovation May Contribute to Slowing the Dissemination of Multiresistant Streptococcus pneumoniae: The Example of Ketolides
por: Opatowski, Lulla, et al.
Publicado: (2008)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Correction: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle
por: Pretto, Francesca, et al.
Publicado: (2016)

The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma
por: Nagaya, Naoya, et al.
Publicado: (2018)

Correction: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Publicado: (2021)

The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors
por: Small, Jeffrey, et al.
Publicado: (2017)

Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
por: Yildiz, Ibrahim, et al.
Publicado: (2014)

Pneumatosis cystoides intestinalis linked to sunitinib treatment for renal cell carcinoma
por: Shikuma, Hiroyuki, et al.
Publicado: (2019)

Correction to: Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals
por: Zhai, Wei, et al.
Publicado: (2022)

Correction: Dual pathway for metabolic engineering of Escherichia coli to produce the highly valuable hydroxytyrosol
Publicado: (2019)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Spindle cell renal cell carcinoma diagnosed after sunitinib treatment for chromophobe renal cell carcinoma
por: Honda‐Takinami, Ruriko, et al.
Publicado: (2020)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Key sunitinib‐related biomarkers for renal cell carcinoma
por: Peng, Yun, et al.
Publicado: (2021)

Correction: The path to « the Golden Age » for the treatment of metastatic renal cell carcinoma
por: Pagès, Gilles
Publicado: (2018)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Correction to: Late initiation of antiretroviral therapy: inequalities by educational level despite universal access to care and treatment
por: Rodrigues, Amanda, et al.
Publicado: (2021)

Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib
por: Gruenwald, Viktor, et al.
Publicado: (2010)

An Unusual Metastatic Renal Cell Carcinoma with Maintained Complete Response to Sunitinib Treatment
por: Chara, Luis, et al.
Publicado: (2011)

Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma
por: Schlemmer, Marcus, et al.
Publicado: (2019)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
por: Lin, Harrison Sicheng, et al.
Publicado: (2022)

Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma
por: Czarnecka, Anna M., et al.
Publicado: (2019)

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients
por: Numakura, Kazuyuki, et al.
Publicado: (2018)

Correction: Continental synchronicity of human influenza virus epidemics despite climactic variation
por: Geoghegan, Jemma L., et al.
Publicado: (2018)

Correction: Long Branch Effects Distort Maximum Likelihood Phylogenies in Simulations Despite Selection of the Correct Model
por: Kück, Patrick, et al.
Publicado: (2012)

Correction to: Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy
por: Wenzler, Eric, et al.
Publicado: (2022)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

Correction to: ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma
por: Chen, Qian, et al.
Publicado: (2021)

Correction: Health Is Still Social: Contemporary Examples in the Age of the Genome
por: Holtz, Timothy H, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_n50e56gmm05hm2f4hk6mls8fe4